Blog

Hauling in a $100M mega-round, gene therapy startup Generation Bio builds alternative to potentially risky viral vectors – Endpoints News


Endpoints News

Hauling in a $100M mega-round, gene therapy startup Generation Bio builds alternative to potentially risky viral vectors
Endpoints News
A gene therapy company headed up by bigwigs and backed early on by Atlas has pulled in a mega-round of $100 million. The 2-year-old startup captured investors' attention by suggesting it knows a better way to do gene transfer than the potentially toxic
Fidelity gets in on $100M round for gene therapy startup Generation BioBoston Business Journal


Generation Bio Announces $100 Million Series B Financing to Advance GeneWave™ Platform for Re-Dosable GeneBusiness Wire (press release)

all 4 news articles »

2018-02-27 NEWS
About Michael Zand

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.